

Pregnancy, Infection, and Refugee Health: A Study on Seroprevalence of Key Pathogens in Turkey's Refugee Population

Gebelik, Enfeksiyon ve Sığınmacı Sağlığı: Türkiye'deki Sığınmacılarda Önemli Patojenlerin Seroprevalansı Üzerine Bir Çalışma

İlkay Akbulut¹, D Zeynep Sedef Varol²

¹University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital, Clinic o of Infectious Diseases and Clinical Microbiology, İzmir, Turkey

²İzmir Health Directorate, Department of Public Health, İzmir, Turkey

Cite as: Akbulut İ, Varol ZS. Pregnancy, Infection, and Refugee Health: A Study on Seroprevalence of Key Pathogens in Turkey's Refugee Population. Anatol J Gen Med Res. 2024;34(3):292-7

Abstract

Objective: Pregnant refugees in Turkey are at high risk for infectious diseases due to limited access to healthcare services and suboptimal hygiene conditions. This study aims to assess the risks posed by infections, particularly toxoplasmosis, Rubella, hepatitis, human immunodeficiency virus (HIV), and cytomegalovirus (CMV), during pregnancy. These pathogens have adverse effects on maternal and fetal health during gestation, and early diagnosis and management are crucial.

Methods: This retrospective study analyzes serological test results from pregnant refugees who presented at University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital between March 1, 2018, and March 1, 2020. Tests evaluated included anti-Toxoplasma immunoglobulin (Ig)M, anti-Toxoplasma IgG, anti-hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), anti-HIV, anti-HBs, anti-Rubella IgM, anti-Rubella IgG, anti-CMV IgM, and anti-CMV IgG. Seroprevalence rates were analyzed annually.

Results: Of the pregnant participants, 94.7% were Syrian, and 5.3% were Afghan. Seroprevalence rates for Toxoplasma IgG, Rubella IgG, and CMV IgG were found to be 51.3%, 85.3%, and 57.6%, respectively. No significant variation in test results was observed over the years. The positive rates for anti-HCV, HBsAg, and anti-Rubella IgM were low; chi-square analysis was limited by low cell frequencies, affecting statistical power.

Conclusion: This study reveals a high prevalence of infections such as toxoplasmosis, Rubella, hepatitis B, and CMV among pregnant refugees in Turkey. Expanding screening and vaccination programs for refugee women is recommended to mitigate infection risks. Improving access to healthcare services and regular screenings is crucial to curbing the spread of these infections.

Keywords: Pregnancy, refugees, seroprevalence



Address for Correspondence/Yazışma Adresi: İlkay Akbulut, University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital, Clinic o of Infectious Diseases and Clinical Microbiology, İzmir, Turkey Received/Geliş tarihi: 02.11.2024 Accepted/Kabul tarihi: 19.11.2024

E-mail: ilkayakbulutdr@gmail.com ORCID ID: orcid.org/0000-0002-4840-6865

Copyright© 2024 The Author. Published by Galenos Publishing House on behalf of University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital. This is an open access article under the Creative Commons AttributionNonCommercial 4.0 International (CC BY-NC 4.0) License.

Öz

Amaç: Türkiye'deki sığınmacı gebeler, sağlık hizmetlerine erişim ve hijyen koşullarındaki kısıtlılıklar nedeniyle enfeksiyon hastalıkları açısından yüksek risk altındadır. Bu çalışma, özellikle toksoplazma, Rubella, hepatit, insan immün yetmezlik virüsü (HIV) ve sitomegalovirüs (CMV) enfeksiyonlarının gebelik sürecinde oluşturduğu riskleri değerlendirmeyi amaçlamaktadır. Bu patojenler, gebelik döneminde anne ve fetüs sağlığı üzerinde olumsuz etkiler yaratabilir ve erken tanı ile yönetilmesi önem taşır.

Yöntem: Bu retrospektif çalışma, 1 Mart 2018-1 Mart 2020 tarihleri arasında Sağlık Bilimleri Üniversitesi, İzmir Tepecik Eğitim ve Araştırma Hastanesi'ne başvuran sığınmacı gebelerin serolojik test sonuçlarını analiz etmektedir. Anti-Toksoplazma immünoglobulin (Ig)M, anti-Toksoplazma IgG, anti-HCV, hepatit B yüzey antijeni (HBsAg), anti-HIV, anti-HBs, anti-Rubella IgM, anti-Rubella IgG, anti-CMV IgM ve anti-CMV IgG testleri değerlendirilmiştir. Yıllara göre seroprevalans oranları analiz edilmiştir.

Bulgular: Çalışmaya katılan gebelerin %94,7'si Suriye, %5,3'ü ise Afganistan uyrukludur. Toksoplazma IgG seroprevalansı %51,3, Rubella IgG %85,3 ve CMV IgG %57,6 olarak bulunmuştur. Test sonuçlarında yıllara göre anlamlı bir değişiklik saptanmamıştır. Anti HCV, HBsAg ve anti Rubella IgM testlerinde pozitiflik oranları düşük kalmıştır, ki-kare analizinde bazı hücre frekanslarının düşük olması nedeniyle istatistiksel güç sınırlanmıştır.

Sonuç: Bu çalışma, Türkiye'deki sığınmacı gebeler arasında toksoplazma, Rubella, hepatit B ve CMV gibi enfeksiyonların yüksek prevalansını göstermektedir. Sığınmacı kadınların enfeksiyon hastalıkları açısından korunması için tarama ve aşı programlarının genişletilmesi önerilmektedir. Sağlık hizmetlerine erişim koşullarının iyileştirilmesi ve düzenli taramalar, bu enfeksiyonların yayılımını azaltmak için kritik öneme sahiptir.

Anahtar Kelimeler: Gebelik, sığınmacılar, seroprevalans

Introduction

Globally, migrant and refugee populations are at high risk for infectious diseases due to restricted access to healthcare and suboptimal hygiene conditions⁽¹⁾. Infections such as toxoplasmosis, Rubella, hepatitis, human immunodeficiency virus (HIV), and cytomegalovirus (CMV) pose significant health concerns, particularly among pregnant women⁽²⁾. The World Health Organization estimates that around 1.5 million people globally are infected with the hepatitis B virus each year, with migrant populations showing higher prevalence rates⁽³⁾. HIV infection rates are also elevated among migrant populations, especially among individuals from low- and middle-income countries^(4,5). Migrants from conflict zones such as Syria and Afghanistan face increased risks for infectious diseases due to poor living conditions, lack of hygiene, and limited access to healthcare services⁽⁶⁾. Infections such as toxoplasmosis, CMV, and Rubella are particularly concerning in these communities. Studies have indicated that toxoplasmosis seroprevalence ranges from 30% to 60%, whereas Rubella seroprevalence remains high among unvaccinated individuals⁽⁷⁻⁹⁾. CMV infection is also prevalent among migrant populations, with transmission risks heightened in environments with inadequate hygiene. Early diagnosis and treatment of these infections are crucial because they can lead to severe complications during pregnancy.

In Turkey, similar patterns are observed among migrant communities. Turkey hosts a large refugee population, particularly from Syria, and the prevalence of infectious diseases within these communities is notably high. Studies among refugee women in Turkey reported hepatitis B carriage rates of approximately 4-7%⁽¹⁰⁾. Although HIV infection is relatively rare among the migrant population in Turkey, it remains a concern in high-risk groups. Infections such as Rubella and CMV can lead to severe complications during pregnancy, affecting both the mother and the fetus. Challenges in accessing healthcare further exacerbate the spread of these infections among refugee populations in Turkey.

Refugee women face economic and social hardships that hinder access to healthcare, increasing the risk of developing infectious diseases. Exposure to infections during pregnancy can result in significant adverse outcomes for both maternal and fetal health⁽¹¹⁾. Screening for infections during pregnancy is crucial to safeguard maternal health and ensure the birth of a healthy child. Specifically, infections such as toxoplasmosis, hepatitis, Rubella, HIV, and CMV can lead to complications during pregnancy and pose risks to the infant's health postpartum⁽¹²⁾. Preventive measures against these infections are essential to minimize potential health risks⁽¹³⁾.

Regular serological testing of pregnant women presenting to University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital is crucial for assessing the prevalence of infection in this group. This study aimed to analyze the annual distribution of serological test results for specific infectious agents among pregnant refugee women admitted to University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital between March 2018 and March 2020. The study examined anti-Toxoplasma IgM, anti-Toxoplasma IgG, anti-HCV, HBsAg, anti-HIV, anti-HBs, anti-Rubella IgM, anti-Rubella IgG, anti-CMV IgM, and anti-CMV IgG tests.

Materials and Methods

This study evaluated the annual distribution of serological test results among pregnant women who presented to University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital between March 1, 2018 and March 1, 2020. The study aims to determine immunity or infection status against certain infectious agents in pregnant women, including anti-Toxoplasma IgM, anti-Toxoplasma IgG, anti-HCV, HBsAg, anti-HIV, anti-HBs, anti-Rubella IgM, anti-Rubella IgG, anti-CMV IgM, and anti-CMV IgG serological tests. Annual positivity, negativity, and untested (not examined) rates for each serological test were analyzed.

Statistical Analysis

In data analysis, the distribution percentages of positive, negative, and untested results for each serological test were calculated by years. The positivity, negativity, and untested rates for each serological test were compared, and the chi-square test was applied to detect differences between years when the validity conditions were met. For test groups with cell frequencies below 5, only percentage summaries were provided because of the invalidation of the test under these conditions. The percentage distribution of positivity and negativity rates in the serological tests was presented using descriptive statistics, and seroprevalence was calculated.

The study was approved by the University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital Ethics Committee on March 06, 2024, with approval number 2024/02-07.

Results

The mean age of the study population was 25.6 ± 3.9 years (range: 18-39). Of the pregnant women, 94.7% (n=1,042) were of Syrian nationality, while the remaining 5.3% (n=58) were of Afghan nationality. Serological testing was conducted for 552 women (50.2%) in 2018, 225 women (20.5%) in 2019, and 323 women (29.4%) up to March 1, 2020.

The seroprevalence of anti-Toxoplasma IgM and anti-Toxoplasma IgG was 2.81% and 51.28% (Table 1). For anti-HCV, the seroprevalence was 0.37%; for HBsAg, 1.85%; and for anti-HBs, 22.29% (Table 2). Anti-Rubella IgM and antiRubella IgG seroprevalence was 0.64% and 85.30% (Table 3). The seroprevalence of anti-CMV IgM was 3.49%, and for anti-CMV IgG was 3.49% and 57.55% (Table 4).

No significant changes were observed in the distribution of serological test results across years within the study group. Although anti-Toxoplasma IgM and IgG positivity rates were higher in 2018, they remained stable in 2019 and 2020 (p>0.05). Due to the low positivity in anti-HCV, HBsAg, and anti-Rubella IgM tests, chi-square analysis was limited by the expected cell counts below 5 for certain categories. Additionally, no significant changes were found across years in anti-HIV, anti-HB, and anti-Rubella IgG levels, with p-values exceeding 0.05. The positivity rates for anti-

Table 1. Distribution of toxoplasma serology results of the study group

Anti Toxoplasma IgM				
Positive (%)	22 (2%)			
Negative (%)	761 (69.2%)			
Not tested (%)	317 (28.8%)			
Anti Toxoplazma IgG				
Positive (%)	402 (36.6%)			
Negative (%)	380 (34.5%)			
Not tested (%)	318 (28.9%)			
lg: Immunoglobulin				

Table 2. Distribution of hepatitis and HIV serology results of the study group

Anti HCV				
Positive (%)	4 (0.4%)			
Negative (%)	1081 (98.3%)			
Not tested (%)	15 (1.3%)			
HBsAg				
Positive (%)	20 (1.8%)			
Negative (%)	1063 (96.6%)			
Not tested (%)	17 (1.6%)			
Anti HBs				
Positive (%)	173 (15.7%)			
Negative (%)	603 (54.8%)			
Not tested (%)	324 (29.5%)			
Anti HIV				
Positive (%)	0 (0.0%)			
Negative (%)	1065 (96.8%)			
Not tested (%)	35 (3.2%)			
HIV: Human immunodeficiency virus, HCV: Hepatitis C virus, HBsAg: Hepatitis B surface antigen				

CMV IgM and IgG were similarly distributed across years, with annual differences not reaching statistical significance (p>0.05). Overall, no notable annual increase or decrease was observed in serological test results; statistical analyses were limited to certain tests due to low cell counts. These findings indicated no significant year-over-year changes in the serological test results of the study group (Table 5).

Discussion

This study revealed the seroprevalence of various infectious agents among pregnant refugee women in Turkey, highlighting infectious disease risks as a significant public health concern in migrant populations. The high prevalence of infections, including toxoplasmosis, Rubella, hepatitis B, HCV, and CMV, in this group is associated with challenges in accessing healthcare and insufficient hygiene conditions. A global review by Saseetharran et al.⁽¹⁴⁾ noted that viral hepatitis infections such as hepatitis B and C are widespread among migrant populations, and barriers to accessing healthcare complicate the treatment and monitoring of these diseases. This finding aligns with our study results, underscoring the importance of expanding viral hepatitis screening among pregnant refugee women⁽¹⁴⁾.

Table 3. Distribution of Rubella serology results of the study group				
Anti Rubella IgM				
Positive (%)	5 (0.5%)			
Negative (%)	779 (70.8%)			
Not tested (%)	316 (28.7%)			
Anti Rubella IgG				
Positive (%)	570 (36.7%)			
Negative (%)	118 (10.7%)			
Not tested (%)	315 (28.6%)			
lg: Immunoglobulin				

Table 4. Distribution of cytomegalovirus serology results of the study group

Anti CMV IgM				
Positive (%)	22 (2%)			
Negative (%)	610 (55.5%)			
Not tested (%)	468 (42.5%)			
Anti CMV IgG				
Positive (%)	633 (57.6%)			
Negative (%)	0 (0%)			
Not tested (%)	467 (42.4%)			
Ig: Immunoglobulin, CMV: Cytomegalovirus				

In our study, the Rubella IgG seropositivity was 85.3%. Similarly, a study by Gürses et al.⁽¹⁵⁾ on Syrian refugees in Şanlıurfa found a high Rubella seropositivity rate (99.5%). This high seropositivity may be attributed to widespread Rubella vaccination or natural immunity among refugees. However, a study by Fahme et al.⁽¹⁶⁾ on sexually transmitted infections in pregnant Syrian refugees in Lebanon indicated that this population does not receive adequate screening services during the antenatal period. This finding highlights the need to expand screening programs for detecting infections during pregnancy.

The prevalence of hepatitis B and C infections among refugee women is also noteworthy. In a study by Hansu and Cikim⁽¹⁷⁾, anti-HCV positivity was found to be higher in Syrian migrant pregnant women in Turkey compared to Turkish pregnant women, which may be linked to poor hygiene and inadequate healthcare services. In our study, anti-HCV seroprevalence was found to be 0.37%, which is lower than in other studies; however, expanding health screenings among refugee populations remains essential to reduce potential transmission risks.

CMV infection can cause serious complications during pregnancy and is more common in communities with poor hygiene. A study by Köse et al.⁽¹⁸⁾ on Syrian refugee children in İzmir reported high CMV seroprevalence, which was linked to the hygiene conditions among refugees. Similarly, our study found a CMV IgG positivity rate of 57.6%, which is consistent with other findings in the literature. CMV screening during pregnancy is critical to reduce the risk of prenatal infection.

Toxoplasma infection is more prevalent in developing countries and poses serious risks to fetal health during the prenatal period. A study conducted in Kahramanmaraş found high toxoplasma seropositivity among Syrian refugee women⁽¹⁹⁾. Similar findings were observed in a study by Hansu et al.⁽²⁰⁾, which reported high toxoplasma seroprevalence among refugee women, associating it with increased hygiene issues due to displacement. Consistent with these studies, our study found a toxoplasma IgG positivity rate of 51.3%, indicating the impact of poor hygiene conditions and limited access to healthy nutrition.

Study Limitations

This study has several limitations. First, it employed a retrospective design and included only pregnant refugee women presenting to University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital. Therefore, the findings cannot be generalized to the entire refugee population

Serological testVear of serological testChi-square test2018 0 (%)2019 0 (%)2020 0 (%)2010 0 (%)Anti-Joongtame Igent(%)9 (40.9%)6 (27.3%)Negative7 (30.8%)9 (40.9%)6 (27.3%)0.09Notested37 (40.5%)15 (10.8%)23 (30.6%)0.09Notested168 (53.%)6 (20.5%)8 (40.5%)0.09Anti-Joongtame Igent19 (47.5%)7 (10.4%)13 (31.1%)0.09Notested166 (52.8%)6 (20.6%)8 (40.6%)0.03Notested166 (52.8%)6 (20.6%)8 (40.6%)0.03Notested260.0%)10 (20.7%)3 (30.1%)0.04Negative59 (50.9%)24 (20.7%)3 (20.9%)0.04Notested10 (50.0%)10 (57%)3 (20.0%)0.04Notested10 (50.0%)10 (20.5%)3 (20.9%)0.04Notested10 (50.0%)10 (20.5%)3 (20.9%)0.04Notested10 (50.0%)10 (20.5%)3 (20.9%)0.04Notested10 (50.0%)10 (20.5%)3 (20.9%)0.04Notested10 (50.0%)10 (20.5%)3 (20.9%)0.04Notested10 (50.0%)10 (20.5%)3 (20.9%)0.04Notested10 (20.9%)10 (20.7%)3 (20.9%)0.04Notested10 (20.9%)10 (20.9%)10 (20.9%)0.04Notested10 (20.9%)10 (20.9%)10 (20.9%)0.04Notested10 (20.9%) <td< th=""><th colspan="7">Table 5. Evaluation of the distribution of serologic test results of the study group according to years</th></td<>	Table 5. Evaluation of the distribution of serologic test results of the study group according to years						
<table-container>D08 0(%)D09 0(%)D09 0(%)D09 0(%)Ant-Toxoplazma L90Ant-Toxoplazma L90Negative77 (45.%)51 (13.%)62.7.%)D09Notested650.%)51 (13.%)242.6.%)D09Ant-Toxoplazma L9015 (13.%)13 (13.%)D09D09Notested160.5%)62.0.%)10 (10.%)D09D09Notested160.5%)62.0.%)10 (10.%)D09D09Notested160.5%)62.0.%)10 (10.%)D09D09Notested160.5%)62.0.%)10 (10.%)D09D09Notested160.5%)10.0%10 (10.%)20.0%)D09Notested10 (10.%)10.0%10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)10 (10.%)D09D09Notested10 (10.%)10 (10.%)</table-container>	Serological test	Year of serological testing			Chi-square test statistic		
n(%)n(%)n(%)n(%)productAnti-Taxoplazma IgMNegative7(31.8%)9(40.9%)6(27.3%)0.091Negative136 (53%)15(1.9.8%)233 (30.6%)0.091Not tested136 (53%)65 (20.5%)84 (26.5%)0Anti-Taxoplasma IgC133 (53.1%)133 (33.1%)136 (27.9%)0.039Negative193 (50.8%)61 (20.3%)106 (27.9%)0.039Not tested138 (52.8%)62 (20.8%)106 (27.9%)0.039Not tested198 (62.8%)0 (0.0%)131 (29.4%)0.039Not tested10 (50.0%)16 (20.7%)31 (20.4%)0.010Not tested11 (73.3%)16 (27.9%)31 (29.4%)0.010Not tested10 (50.0%)214 (20.7%)31 (29.4%)0.010Not tested10 (50.0%)216 (20.7%)31 (29.4%)0.010Not tested10 (50.0%)216 (20.5%)31 (29.5%)0.011Not tested10 (50.0%)216 (20.5%)31 (29.5%)0.011Not tested20 (90.7%)216 (20.7%)316 (29.7%)0.011Not tested20 (90.7%)216 (20.5%)31 (29.5%)0.011Not tested20 (50.7%)216 (20.5%)31 (29.5%)0.011Not tested20 (90.7%)216 (20.7%)316 (29.7%)0.011Not tested20 (90.7%)216 (20.5%)31 (29.5%)0.011Not tested20 (90.7%)216 (20.5%)31 (29.5%)0.011Not tested20 (2018	2019	2020	n value		
<table-container>Anti-Scoplazma IgMPositive7 (31.6%)9(4.0.9%)6 (27.3%)Positive377 (49.5%)151 (19.8%)233 (30.6%)Not tested168 (53%)65 (20.5%)84 (26.5%)Anti-Scoplasma IgG78 (19.4%)133 (31.9%)PositivePositive191 (47.5%)81 (21.3%)106 (27.9%)PositiveNot tested192 (50.6%)81 (21.3%)106 (27.9%)PositiveNot tested193 (50.6%)81 (21.3%)106 (27.9%)PositivePositive2 (50.0%)0 (0.0%)2 (50.0%)PositiveNot tested10 (73.0%)1 (6.7%)318 (29.4%)PositiveNot tested10 (73.0%)1 (6.7%)318 (29.4%)PositiveNot tested10 (73.0%)1 (6.7%)318 (29.4%)PositiveNot tested10 (50.0%)1 (6.7%)318 (29.4%)PositiveNot tested10 (50.0%)2 (20.7%)318 (29.4%)PositiveNot tested10 (50.0%)4 (20.0%)314 (29.5%)PositiveNot tested166.7%)2 (16.9%)314 (29.5%)PositiveNot tested166.7%)2 (16.9%)316 (29.7%)PositiveNot tested169.7%)2 (20.7%)316 (29.7%)PositiveNot tested169.7%)2 (20.7%)316 (29.7%)PositiveNot tested160.7%)2 (16.9%)316 (29.7%)PositiveNot tested169.7%)2 (20.7%)316 (29.7%)PositiveNot tested169.7%)10 (29.7</table-container>		n (%)	n (%)	n (%)	p-value		
<table-container>Positive7 (31.8%)9 (40.9%)6 (23.9%)Negative377 (49.5%)151 (19.8%)233 (30.6%)0.091Not tested196 (33%)65 (20.5%)84 (26.5%)Atti-Anti-Toxoplasma IgG193 (50.8%)61 (21.3%)106 (27.9%)0.33Negative193 (50.8%)61 (20.4%)104 (27.9%)0.33Not tested196 (52.8%)66 (20.8%)84 (26.4%)Atti-Anti-HCV2 (50.0%)2 (50.0%)2 (50.0%)316 (29.4%)Not tested10 (90.0%)2 (50.0%)3 (20.0%)Atti-Not tested10 (90.0%)1 (6.7%)3 (20.0%)Atti-Not tested10 (90.0%)2 (10.0%)3 (12.5%)Atti-Not tested10 (90.0%)2 (10.0%)3 (12.5%)Atti-Not tested10 (90.0%)2 (10.0%)3 (12.9%)Atti-Not tested10 (90.0%)2 (10.0%)3 (12.9%)Atti-Not tested23 (85.7%)2 (10.2%)3 (12.9%)Atti-Not tested23 (85.7%)5 (14.3%)7 (20.4%)Atti-Not tested29 (49.4%)12 (20.7%)3 (12.9%)Atti-Not tested29 (49.4%)12 (20.5%)3 (40.9%)Atti-Not tested29 (40.4%)12 (20.5%)3 (40.9%)Atti-Not tested29 (40.4%)12 (20.7%)3 (40.9%)Atti-Not tested32 (40.9%)12 (20.5%)3 (40.9%)Atti-Not tested32 (40.9%)12 (20.5%)3 (30.9%)Atti</table-container>	Anti-Toxoplazma IgM						
<table-container>Negative377 (49.5%)151 (19.8%)23 (30.6%)0.091Not tested168 (53%)65 (20.5%)84 (26.5%)7Negative191 (47.5%)78 (19.4%)133 (33.1%)106 (27.9%)Negative193 (50.8%)61 (21.3%)106 (27.9%)3Not tested168 (53%)66 (20.8%)84 (26.5%)3Anti-HCO100.5%)66 (20.8%)24 (20.7%)318 (29.4%)3Not tested107 (33%)1 (6.7%)3 (20.0%)4Not tested107 (33%)1 (6.7%)3 (20.0%)4Not tested10 (50.0%)4 (20.0%)6 (30.0%)4Not tested10 (50.0%)216 (20.5%)314 (22.5%)3Not tested10 (50.0%)210 (20.5%)3 (10.6%)3Not tested10 (50.0%)20 (20.7%)3 (16.29.7%)1.0%Not tested10 (50.0%)5 (4.3%)7 (20.0%)1.0%Not tested23 (50.0%)5 (13.5%)7 (20.0%)1.0%Anti-HV23 (55.7%)5 (4.3%)7 (20.9%)1.0%Not tested23 (48.0%)3 (17.9%)7 (20.9%)0.04Not tested10 (26.5%)3 (17.9%)8 (26.9%)0.04Not tested10 (26.0%)3 (17.9%)8 (26.9%)0.04Not tested10 (26.0%)3 (17.9%)8 (26.9%)0.04Not tested10 (26.0%)3 (17.9%)2.00.0%)0.04Not tested10 (26.0%)10 (20.0%)2.00.0%0.04Not test</table-container>	Positive	7 (31.8%)	9 (40.9%)	6 (27.3%)			
Not testedI68 (33%)65 (20.5%)84 (26.5%)IAnti-toxoplasma IgG78 (19.4%)133 (33.1%)33 (33.1%)33 (33.1%)Negative193 (50.8%)81 (21.3%)106 (27.9%)0.339Not tested168 (52.8%)66 (20.8%)84 (26.4%)***Anti-HCV539 (49.9%)24 (20.7%)318 (29.4%)***Positive2 (50.0%)10.0%)2 (50.0%)***Not tested10 (50.0%)24 (20.7%)318 (29.4%)***Not tested10 (50.0%)4 (20.0%)6 (30.0%)***Positive531 (50.0%)218 (20.5%)314 (29.5%)***Not tested10 (50.0%)218 (20.5%)314 (29.5%)***Not tested10 (50.0%)218 (20.5%)314 (29.5%)***Not tested13 (50.0%)218 (20.5%)314 (29.5%)***Not tested23 (60.7%)20 (20.7%)316 (29.7%)***Not tested23 (49.7%)20 (20.7%)316 (29.7%)***Not tested23 (49.0%)13 (17.9%)59 (34.1%)***Not tested34 (40.0%)13 (17.9%)59 (34.1%)***Not tested32 (49.0%)10 (20.3%)414 (21.3%)414 (21.3%)Not tested13 (29.0%)16 (20.5%)24 (30.4%)***Not tested26 (40.9%)10 (20.3%)40 (49.4%)***Not tested32 (49.0%)16 (20.5%)414 (21.3%)556Not tested36 (49.9%)16 (20.5%)*** </td <td>Negative</td> <td>377 (49.5%)</td> <td>151 (19.8%)</td> <td>233 (30.6%)</td> <td>0.091</td>	Negative	377 (49.5%)	151 (19.8%)	233 (30.6%)	0.091		
<table-container>Anti-Toxoplasma lgGPositive191 (47,5%)78 (19,4%)133 (33,1%)Negative193 (50,8%)81 (21,3%)106 (27,9%)Not tested166 (52,8%)64 (26,4%)84 (26,4%)Anti-HCV66 (20,8%)84 (26,4%)100Positive2 (50,0%)24 (20,7%)316 (29,4%)Negative1 (7,3%)10,7%)316 (29,4%)Not tested1 (7,3%)10,7%)316 (29,4%)Positive1 (7,3%)218 (20,5%)340,0%)Not tested10 (50,0%)4 (20,0%)314 (29,5%)Positive1 (16,4%)3176%)316 (29,5%)Not tested1 (16,4%)3176%)316 (29,5%)Not tested1 (29,4%)316 (29,5%)316 (29,5%)Positive23 (59,7%)220 (20,7%)316 (29,7%)Not tested1 (29,4%)31 (17,9%)316 (29,7%)Not tested23 (59,7%)126 (29,7%)316 (29,7%)Not tested13 (40,0%)31 (17,9%)59 (31,4%)Not tested13 (40,0%)31 (17,9%)59 (31,4%)Not tested13 (20,0%)126 (29,6%)10,4%)Not tested13 (20,0%)126 (29,6%)10,4%)Not tested13 (20,0%)126 (29,6%)10,4%)Not tested13 (20,0%)160 (20,5%)27 (30,4%)Not tested13 (20,0%)160 (20,5%)27 (30,4%)Not tested13 (20,0%)160 (20,5%)27 (30,4%)Not tested13 (20,0%)16 (20,5%)27 (30,4%)<</table-container>	Not tested	168 (53%)	65 (20.5%)	84 (26.5%)			
<table-container>Positive191 (475%)76 (19.4%)133 (33.1%)ApproximatelyNegative193 (50.8%)81 (21.3%)16 (62.9%)64 (62.9%)Not tested168 (52.8%)66 (20.8%)84 (62.9%)Arti-HCV260.0%)2 (50.0%)2Negative539 (49.9%)224 (20.7%)318 (29.4%)***Not tested179.9%)224 (20.7%)318 (29.4%)***HBSA10 (50.0%)4 (20.0%)63.00%)***Not tested10 (50.0%)4 (20.0%)314 (29.5%)***Not tested10 (50.0%)218 (20.5%)314 (29.5%)***Not tested10 (50.0%)218 (20.5%)314 (29.5%)***Not tested10 (50.0%)218 (20.5%)314 (29.5%)***Not tested10 (50.0%)218 (20.7%)316 (29.7%)***Not tested234 (57.9%)204 (20.7%)316 (29.7%)***Not tested23 (57.9%)204 (20.7%)316 (29.7%)***Not tested23 (57.9%)204 (20.7%)316 (29.7%)***Not tested23 (49.7%)204 (20.7%)316 (29.7%)***Not tested28 (49.9%)31 (17.9%)59 (34.1%)***Not tested302 (49.0%)160 (20.5%)27 (30.4%)***Not tested36 (49.9%)160 (20.5%)27 (30.4%)***Not tested36 (49.9%)160 (20.5%)27 (30.4%)***Not tested30 (40.9%)100 (20.5%)27 (30.4%)***<t< td=""><td>Anti-Toxoplasma IgG</td><td></td><td></td><td></td><td></td></t<></table-container>	Anti-Toxoplasma IgG						
Negative193 (50.8%)61 (21.3%)106 (27.9%)0.339Not tested160.2%)64 (26.4%)44 (26.4%)Anti-HCV539 (49.9%)224 (20.7%)318 (29.4%)***Negative539 (49.9%)224 (20.7%)318 (29.4%)***Not tested10 (50.0%)1 (6.7%)318 (29.4%)***HBAG10.50.0%)4 (20.0%)6 (30.0%)***Positive531 (50.0%)218 (20.5%)314 (29.5%)***Not tested10 (50.0%)4 (20.0%)6 (30.0%)***Not tested10 (50.0%)218 (20.5%)316 (29.7%)Not tested23 (57.%)20 (20.7%)316 (29.7%)Not tested23 (56.7%)5 (14.3%)7 (20.0%)Anti-HB20 (20.7%)316 (29.7%)Not tested23 (56.7%)5 (14.3%)7 (20.0%)Not tested298 (49.4%)120 (20.7%)107 (29.4%)Not tested17 (52.8%)6 (60.4%)87 (66.9%)Not tested17 (52.8%)6 (20.4%)87 (30.9%)Negative298 (49.4%)128 (21.2%)177 (29.4%)Not tested10 (20.0%)16 (20.5%)82 (30.0%)Negative298 (49.0%)16 (20.0%)82 (30.0%)Not tested10 (20.0%)16 (20.5%)27 (30.4%)Not tested17 (52.8%)160 (20.5%)36 (33.1%)Not tested16 (5	Positive	191 (47.5%)	78 (19.4%)	133 (33.1%)			
Not ested168 (52.8%)66 (20.8%)84 (26.4%)Anti-HCVPositive2 (50.0%)2 (50.0%)2 (50.0%)Negative539 (49.9%)224 (20.7%)318 (29.4%)Not tested1 (73.3%)1 (6.7%)3 (20.0%)HBSA1 (73.3%)1 (6.7%)3 (20.0%)HSAQ1 (50.0%)4 (20.0%)6 (30.0%)Negative10 (50.0%)218 (20.5%)3 (14 (29.5%)Not tested10 (60.7%)218 (20.5%)3 (12.9%)Not tested10 (65.7%)20 (20.7%)3 (16 (29.7%)Not tested259 (49.7%)20 (20.7%)3 (16 (29.7%)Not tested259 (49.7%)20 (20.7%)3 (16 (29.7%)Not tested259 (49.7%)20 (20.7%)3 (16 (29.7%)Not tested259 (49.7%)20 (20.7%)3 (16 (29.7%)Not tested299 (49.4%)120 (20.7%)3 (16 (29.7%)Not tested298 (49.4%)120 (20.6%)177 (29.4%)Not tested17 (52.8%)66 (20.4%)87 (26.9%)Not tested20 (20.0%)120 (20.5%)237 (30.4%)Not tested20 (20.0%)120 (20.5%)237 (30.4%)Not tested36 (20.9%)160 (20.5%)237 (30.4%)Not tested26 (40.9%)10 (20.5%)237 (30.4%)Not tested20 (20.0%)120 (20.3%)126 (20.3%)Not tested20 (20.9%)120 (20.3%)126 (20.3%)Not tested20 (20.9%)120 (20.3%)126 (20.3%)Not tested10 (55.5%)	Negative	193 (50.8%)	81 (21.3%)	106 (27.9%)	0.339		
Anti-HCVPositive2 (50.0%)0 (0.0%)2 (50.0%)Negative539 (49.9%)224 (20.7%)318 (29.4%)Not tested1 (7.3.3%)1 (6.7%)3 (20.0%)HBSA1 (7.3.3%)1 (6.0%)6 (30.0%)Positive10 (50.0%)4 (20.0%)6 (30.0%)Negative10 (50.0%)218 (20.5%)314 (29.5%)Not tested11 (64.7%)3 (17.6%)34 (29.5%)Anti-HU10 (60.0%)210 (20.7%)316 (29.7%)Not tested23 (65.7%)5 (14.3%)7 (20.0%)Anti-HBB220 (20.7%)316 (29.7%)AngentPositive83 (48.0%)31 (17.9%)5 (34.1%)Negative28 (49.4%)120 (21.2%)17 (29.4%)Not tested298 (49.4%)120 (20.5%)37 (30.4%)Negative240.0%)160 (20.5%)37 (30.4%)Not tested120.0%)120.0%)40.49Not tested362 (49.0%)160 (20.5%)37 (30.4%)Negative362 (49.0%)160 (20.5%)37 (30.4%)Not tested160 (20.5%)27 (30.4%)164Negative326 (49.0%)160 (20.5%)37 (30.4%)Not tested160 (20.5%)27 (30.4%)164Not tested160 (20.5%)37 (30.4%)164Negative326 (49.0%)160 (20.5%)31 (30.1%)Not tested160 (20.5%)163 (20.%)164Not tested160 (20.5%)163 (20.%)164Not tested160 (20.5%) <t< td=""><td>Not tested</td><td>168 (52.8%)</td><td>66 (20.8%)</td><td>84 (26.4%)</td><td></td></t<>	Not tested	168 (52.8%)	66 (20.8%)	84 (26.4%)			
<table-container>Positive2 (50.0%)0 (0.0%)2 (50.0%)seaNegative539 (49.9%)24 (20.7%)318 (29.4%)seaNot tested11 (73.3%)1 (6.7%)3 (20.0%)seaHBSAG</table-container>	Anti-HCV						
Negative539 (49.9%)224 (20.7%)318 (29.4%)****Not tested11 (73.3%)16.7%)3 (20.0%)****HBsAg11 (73.3%)4 (20.0%)6 (30.0%)****Negative531 (50.0%)218 (20.5%)314 (29.5%)****Not tested11 (64.7%)3 (17.6%)3 (17.6%)****Anti-HIV11 (64.7%)20 (20.7%)316 (29.7%)****Not tested23 (65.7%)20 (20.7%)316 (29.7%)****Not tested23 (65.7%)5 (14.3%)7 (20.0%)****Anti-HIV23 (65.7%)5 (14.3%)7 (20.0%)****Not tested23 (65.7%)12 (21.2%)177 (29.4%)0.491Not tested17 (52.8%)66 (20.4%)87 (20.9%)0.491Not tested17 (52.8%)66 (20.4%)87 (20.9%)****Positive240.0%)120.0%)240.0%)****Not tested108 (53.2%)64 (20.3%)84 (26.6%)****Not tested168 (53.2%)64 (20.3%)84 (26.6%)****Not tested160 (20.5%)20 (10.0%)30 (30.0%)****Not tested160 (20.5%)39 (33.1%)********Positive59 (50.0%)20 (16.9%)39 (33.1%)****Not tested160 (20.3%)44 (20.3%)84 (26.7%)****Not tested160 (20.5%)141 (21.1%)200 (30.0%)****Not tested160 (20.9%)141 (21.9%)163 (20.9%)**** <tr< td=""><td>Positive</td><td>2 (50.0%)</td><td>0 (0.0%)</td><td>2 (50.0%)</td><td></td></tr<>	Positive	2 (50.0%)	0 (0.0%)	2 (50.0%)			
Not tested11 (73.3%)1 (6.7%)3 (20.0%)HBsAgHSted10 (50.0%)4 (20.0%)6 (30.0%)Negative531 (50.0%)218 (20.5%)314 (29.5%)Not tested11 (64.7%)3 (17.6%)3 (17.6%)Anti-HIV220 (20.7%)3 (62.97%)3 (62.97%)Not tested23 (65.7%)5 (14.3%)7 (20.0%)Anti-HBS5 (14.3%)7 (20.0%) 0.176 Sotitve83 (48.0%)3 (17.9%)5 (93.1%) 0.176 Not tested298 (49.4%)128 (21.2%)177 (29.4%) 0.491 Not tested298 (49.4%)128 (21.2%)177 (29.4%) 0.491 Not tested298 (49.4%)128 (21.2%)377 (20.4%) 0.491 Negative298 (49.4%)128 (21.2%)377 (29.4%) 0.491 Not tested10 (52.8%)64 (20.3%)84 (26.9%) 0.491 Not tested168 (53.2%)64 (20.3%)84 (26.9%) 0.566 Not tested167 (53.0%)20 (16.9%)39 (33.1%) 0.566 Not tested167 (53.0%)20 (16.9%)39 (33.1%) 0.566 Not tested10 (45.5%)4 (18.2%)188 (30.8%) 0.604 Not tested10 (45.5%)4 (18.2%)188 (30.8%) 0.604 Not tested208 (50.9%)103 (22.0%)126 (27.1%) 0.604 Not tested208 (50.9%)103 (22.0%)136 (30.0%) 0.604 Not tested208 (50.9%)103 (22.0%)136 (30.0%) 0.604 No	Negative	539 (49.9%)	224 (20.7%)	318 (29.4%)	****		
<table-container>HBsAgPositive10 50.0%4 20.0%6 30.0%Negative313 (50.0%218 (20.5%)31 (20.5%)Notesde10 64.7%31 (7.6%)31 (20.5%)Ant-HV20 (20.7%)36 (29.7%)100Notesde23 (65.7%)20 (20.7%)36 (29.7%)Notesde23 (65.7%)5 (14.3%)7 (20.0%)Ant-HBs20 (20.7%)36 (39.7%)101Notesde29 (49.7%)12 (20.2%)104Notesde98 (49.4%)12 (20.2%)104Notesde29 (49.4%)12 (20.4%)104Negative29 (49.4%)12 (20.4%)104Notesde29 (49.4%)12 (20.4%)104Negative20 (40.0%)12 (00.4%)104Negative32 (49.0%)16 (20.5%)37 (30.4%)Negative32 (49.0%)16 (20.5%)37 (30.4%)Negative32 (49.0%)16 (20.5%)31 (30.4%)Negative32 (49.0%)16 (20.3%)16 (20.5%)Negative32 (49.0%)16 (20.3%)104Negative32 (49.0%)16 (20.3%)104Negative32 (49.0%)16 (20.3%)104Negative32 (49.0%)16 (20.3%)104Negative32 (49.0%)16 (20.3%)104Negative32 (49.0%)16 (20.3%)104Negative32 (49.0%)16 (20.3%)104Negative32 (49.0%)16 (20.3%)104Negative32 (49.0%)16 (20.3%)104<!--</td--><td>Not tested</td><td>11 (73.3%)</td><td>1 (6.7%)</td><td>3 (20.0%)</td><td></td></table-container>	Not tested	11 (73.3%)	1 (6.7%)	3 (20.0%)			
Positive10 (50.0%)4 (20.0%)6 (30.0%)Negative531 (50.0%)218 (20.5%)314 (29.5%)Not tested11 (64.7%)3 (17.6%)316 (29.7%)Anti-HIVNegative529 (49.7%)220 (20.7%)316 (29.7%)Not tested23 (65.7%)5 (14.3%)7 (20.0%)Anti-HBsPositive83 (48.0%)31 (17.9%)5 (34.1%)Negative298 (49.4%)128 (21.2%)177 (29.4%)Not tested170 (52.8%)66 (20.4%)87 (69.9%)Not tested171 (52.8%)66 (20.4%)87 (69.9%)Not tested170 (52.8%)160 (20.5%)237 (30.4%)Negative240.0%)160 (20.5%)237 (30.4%)Negative322 (40.0%)160 (20.5%)237 (30.4%)Not tested166 (53.2%)64 (20.3%)84 (26.6%)Positive296 (50.0%)20 (16.9%)39 (33.1%)Not tested167 (53.0%)20 (16.9%)39 (33.1%)Negative296 (49.9%)141 (21.1%)20 (30.0%)Not tested107 (53.0%)20 (16.9%)39 (33.1%)Negative304 (49.8%)118 (19.3%)188 (30.8%)Not tested10 (45.5%)418.2%)8 (36.4%)Negative304 (49.8%)118 (19.3%)188 (30.8%)Not tested30 (49.8%)118 (19.3%)188 (30.8%)Not tested304 (49.8%)138 (21.9%)166 (31.0%)Not tested304 (49.8%)138 (21.9%)164 (30.6%)Not tested <td< td=""><td>HBsAg</td><td></td><td></td><td></td><td></td></td<>	HBsAg						
Negative531 (50.0%)218 (20.5%)314 (29.5%)***Not tested11 (64.7%)3 (17.6%)3 (17.6%)3 (17.6%)Anti-HIVNegative529 (49.7%)220 (20.7%)316 (29.7%)1015Not tested20 (65.7%)5 (1.3%)7 (20.0%)1015Anti-HBSPositive83 (46.0%)31 (17.9%)59 (34.1%)148Not tested298 (49.4%)128 (21.2%)177 (29.4%)0491Not tested298 (49.4%)128 (21.2%)77 (29.4%)0491Not tested171 (52.8%)64 (20.4%)214 (20.6%)414Not tested168 (53.2%)160 (20.5%)237 (30.4%)**Negative382 (49.0%)160 (20.5%)39 (33.1%)**Not tested169 (50.0%)20 (16.9%)39 (33.1%)**Not tested167 (53.0%)20 (16.9%)39 (33.1%)**Not tested167 (53.0%)20 (16.9%)39 (33.1%)**Not tested167 (53.0%)20 (16.9%)39 (33.1%)**Not tested167 (53.0%)20 (16.9%)30 (30.0%)*Not tested167 (53.0%)141 (21.1%)80 (6.8%)*Not tested10 (45.5%)4 (18.2%)8 (36.4%)*Not tested30 (49.8%)118 (19.3%)8 (30.8%)*Not tested30 (49.8%)118 (19.3%)188 (30.8%)*Not tested30 (49.8%)118 (19.3%)183 (30.8%)*Not tested30 (49.8%) <td>Positive</td> <td>10 (50.0%)</td> <td>4 (20.0%)</td> <td>6 (30.0%)</td> <td></td>	Positive	10 (50.0%)	4 (20.0%)	6 (30.0%)			
Not tested11 (64.7%)3 (17.6%)3 (17.6%)Anti-HIVNegative529 (49.7%)220 (20.7%)316 (29.7%)0.175Not tested23 (55.7%)5 (14.3%)7 (20.0%)1.075Anti-HBSPositive63 (48.0%)31 (17.9%)59 (34.1%)0.491Not tested298 (49.4%)126 (21.2%)177 (29.4%)0.491Not tested171 (52.8%)66 (20.4%)87 (26.9%)0.491Anti-Rubelta IgMPositive240.0%)120 (20.5%)2 (40.0%)416 (20.3%)84 (26.6%)Not tested168 (53.2%)64 (20.3%)84 (26.6%)***Positive168 (53.2%)64 (20.3%)84 (26.6%)***Not tested169 (50.0%)20 (16.9%)39 (33.1%).556Not tested169 (50.0%)20 (16.9%)39 (33.1%).556Not tested169 (50.0%)20 (16.9%)39 (33.1%).556Not tested169 (50.0%)20 (16.9%)39 (33.1%).556Not tested169 (50.0%)20 (16.9%)39 (33.1%).556Not tested169 (50.0%)120 (11.9%)120 (20.0%).556Not tested30 (49.8%)118 (19.3%)188 (30.8%).664Not tested104 (55%)118 (19.3%)188 (30.8%).664Not tested238 (50.9%)103 (22.0%)127 (27.9%).664Not tested315 (49.8%)103 (22.0%)126 (30.9%).664Not tested238 (50.9%)103 (22.0%)	Negative	531 (50.0%)	218 (20.5%)	314 (29.5%)	****		
Ahti-HIVNegative529 (49.7%)20 (20.7%)316 (29.7%)Not tested23 (55.7%)5 (14.3%)7 (20.0%)Anti-HBS5 (14.3%)7 (20.0%)Positive83 (48.0%)31 (17.9%)5 (34.1%)Negative98 (49.4%)128 (21.2%)17 (29.4%)Not tested17 (29.4%)17 (29.4%)140.1%Not tested17 (20.0%)6 (60.4%)8 (20.9%)Anti-Hubella IgM1 (20.0%)2 (40.0%)100Not tested2 (40.0%)1 (20.0%)2 (40.0%)Not tested36 (29.4%)16 (20.0%)2 (40.0%)Negative16 (20.0%)2 (40.0%)2 (40.0%)Not tested16 (20.0%)2 (40.0%)10 (20.0%)Not tested16 (50.3%)16 (20.0%)3 (31.1%)Not tested19 (50.0%)2 (16.9%)3 (31.3%)Negative19 (50.0%)2 (16.9%)3 (31.3%)Not tested10 (50.5%)6 (20.3%)6 (20.3%)Not tested10 (45.5%)14 (12.1%)20 (30.0%)Not tested10 (45.5%)14 (12.1%)3 (30.9%)Not tested10 (45.5%)18 (19.3%)16 (40.4%)Not tested10 (45.5%)18 (19.3%)16 (30.9%)Not tested10 (40.9%)13 (20.0%)12 (21.1%)Not tested10 (40.9%)13 (20.0%)12 (21.1%)Not tested10 (40.9%)13 (20.0%)16 (40.9%)Not tested10 (40.9%)13 (20.0%)16 (40.9%)Not tested </td <td>Not tested</td> <td>11 (64.7%)</td> <td>3 (17.6%)</td> <td>3 (17.6%)</td> <td></td>	Not tested	11 (64.7%)	3 (17.6%)	3 (17.6%)			
Negative529 (49.7%)220 (20.7%)316 (29.7%) $)_{175}$ Not tested23 (65.7%)5 (14.3%)7 (20.0%) $)_{175}$ Anti-HBSPositive83 (48.0%)31 (17.9%)59 (34.1%) $)_{174}$ Negative298 (49.4%)128 (21.2%)177 (29.4%) $)_{174}$ Not tested171 (52.8%)66.02.0%)87 (26.9%) $)_{174}$ Anti-Rubella IgM120.0%)2 (40.0%)2 (40.0%) $_{160}$ (20.4%)2 (40.0%)Not tested2 (40.0%)160 (20.5%)237 (30.4%) $_{164}$ Not tested166 (53.2%)64 (20.3%)39 (33.1%) $_{164}$ Not tested59 (50.0%)20 (16.9%)39 (33.1%) $_{154}$ Negative59 (50.0%)20 (16.9%)39 (33.1%) $_{154}$ Not tested167 (53.0%)64 (20.3%)44 (26.7%) $_{164}$ Not tested10 (45.5%)4 (18.2%)8 (36.4%) $_{164}$ Not tested10 (45.5%)118 (19.3%)188 (30.8%) $_{164}$ Not tested304 (49.8%)118 (19.3%)188 (30.8%) $_{164}$ Not tested305 (0.9%)103 (22.0%)127 (27.1%) $_{100}$ Not tested315 (49.8%)122 (19.3%)196 (31.0%) $_{200}$ Not tested315 (49.8%)122 (19.5%)127 (27.2%) $_{200}$ Not tested215 (20.9%)103 (22.1%)127 (27.2%) $_{200}$ Not tested315 (49.8%)122 (19.5%)127 (27.2%) $_{200}$ Not tested <td< td=""><td>Anti-HIV</td><td></td><td></td><td></td><td></td></td<>	Anti-HIV						
Not tested 23 (65.7%) 5 (14.3%) 7 (20.0%) 0.1/3 Anti-HBs Positive 83 (48.0%) 31 (17.9%) 59 (34.1%) Magative Negative 298 (49.4%) 128 (21.2%) 177 (29.4%) 0.491 Not tested 171 (52.8%) 66 (20.4%) 87 (26.9%) 0.491 Anti-Rubella IgM 66 (20.4%) 87 (26.9%) 0.491 Not tested 2 (40.0%) 1 (20.0%) 2 (40.0%) 0.491 Negative 382 (49.0%) 160 (20.5%) 237 (30.4%) *** Not tested 168 (53.2%) 64 (20.3%) 84 (26.6%) *** Not tested 166 (53.2%) 64 (20.3%) 84 (26.6%) *** Positive 59 (50.0%) 20 (16.9%) 39 (33.1%) \$\$ Not tested 167 (53.0%) 64 (20.3%) 84 (26.7%) \$\$ Anti-CMV IgM 10 (45.5%) (418.2%) 84 (36.8%) \$\$ Not tested 304 (49.8%) 118 (19.3%) 188 (30.8%) \$\$ Not tested <td>Negative</td> <td>529 (49.7%)</td> <td>220 (20.7%)</td> <td>316 (29.7%)</td> <td>0 175</td>	Negative	529 (49.7%)	220 (20.7%)	316 (29.7%)	0 175		
Anti-HBsPositive83 (48.0%)31 (17.9%)59 (34.1%)Negative298 (49.4%)128 (21.2%)177 (29.4%)Not tested171 (52.8%)66 (20.4%)87 (20.9%)Anti-Rubella IgM120.0%87 (20.9%)40.0%)Negative240.0%160 (20.5%)237 (30.4%)Not tested186 (53.2%)64 (20.3%)84 (26.6%)Not tested168 (53.2%)64 (20.3%)84 (26.6%)Anti-Rubella IgG161 (20.5%)91 (31.1%)AppleNot tested59 (50.0%)201 (69.9%)91 (31.1%)Not tested167 (53.0%)201 (69.9%)91 (31.0%)Not tested167 (53.0%)64 (20.3%)91 (31.0%)Not tested167 (53.0%)64 (20.3%)91 (31.0%)Not tested10 (45.5%)141 (21.1%)90 (30.0%)Not tested10 (45.5%)141 (21.1%)81 (63.0%)Not tested10 (45.5%)141 (21.3%)81 (63.0%)Not tested10 (45.5%)141 (21.3%)163 (20.4%)Not tested10 (45.5%)181 (93.3%)163 (30.6%)Not tested10 (45.9%)181 (93.3%)163 (30.6%)Not tested10 (45.9%)10 (20.1%)10 (20.1%)Not tested10 (20.7%)10 (20.1%)10 (20.1%)Not tested10 (20.7%)10 (20.1%)10 (20.1%)Not tested10 (20.1%)10 (20.1%)10 (20.1%)Not tested10 (20.1%)10 (20.1%)10 (20.1%)Not tested10 (20.1%) <td< td=""><td>Not tested</td><td>23 (65.7%)</td><td>5 (14.3%)</td><td>7 (20.0%)</td><td>0.175</td></td<>	Not tested	23 (65.7%)	5 (14.3%)	7 (20.0%)	0.175		
Positive83 (48.0%)31 (17.9%)59 (34.1%)PositiveNegative298 (49.4%)128 (21.2%)177 (29.4%)0.491Not tested171 (52.8%)66 (20.4%)87 (26.9%)0.491Anti-Rubella IgM2 (40.0%)1 (20.0%)2 (40.0%)***Positive382 (49.0%)160 (20.5%)237 (30.4%)****Not tested168 (53.2%)64 (20.3%)84 (26.6%)****Positive59 (50.0%)20 (16.9%)39 (33.1%)***Not tested59 (50.0%)20 (16.9%)39 (33.1%)Negative326 (48.9%)141 (21.1%)200 (30.0%)Not tested167 (53.0%)64 (20.3%)84 (26.7%)Positive10 (45.5%)4 (18.2%)8 (36.4%)Not tested10 (49.8%)118 (19.3%)188 (30.8%)Not tested304 (49.8%)103 (22.0%)127 (27.1%)Positive315 (49.8%)122 (19.3%)196 (31.0%)Not tested315 (50.7%)103 (22.1%)127 (27.2%)Positive315 (49.8%)103 (20.5%)270 (20.4%)	Anti-HBs						
Negative298 (49.4%)128 (21.2%)177 (29.4%)0.491Not tested171 (52.8%)66 (02.4%)87 (26.9%)7Anti-Rubella IgM2 (40.0%)1 (20.0%)2 (40.0%)***Negative382 (49.0%)160 (20.5%)237 (30.4%)***Not tested168 (53.2%)64 (20.3%)84 (26.6%)***Positive168 (53.2%)64 (20.3%)84 (26.6%)***Positive59 (50.0%)20 (16.9%)39 (33.1%)***Negative326 (48.9%)141 (21.1%)200 (30.0%)***Not tested167 (53.0%)64 (20.3%)84 (26.7%)***Not tested167 (53.0%)64 (20.3%)84 (36.7%)***Not tested10 (45.5%)4 (18.2%)8 (36.4%)***Negative304 (49.8%)118 (19.3%)188 (30.8%)***Not tested305 (0.9%)103 (22.0%)196 (31.0%)***Positive315 (49.8%)122 (19.3%)127 (27.2%)***Not tested237 (50.7%)103 (22.1%)127 (27.2%)***	Positive	83 (48.0%)	31 (17.9%)	59 (34.1%)			
Not tested171 (52.8%)66 (20.4%)87 (26.9%)Anti-Rubella IgM2 (40.0%)1 (20.0%)2 (40.0%)Negative382 (49.0%)160 (20.5%)237 (30.4%)Not tested382 (49.0%)160 (20.5%)84 (26.6%)Anti-Rubella IgG160 (20.3%)84 (26.6%)Positive59 (50.0%)20 (16.9%)39 (33.1%)Negative59 (50.0%)20 (16.9%)39 (33.1%)Negative167 (53.0%)64 (20.3%)84 (26.7%)Not tested167 (53.0%)64 (20.3%)84 (26.7%)Anti-CMV IgM118 (19.3%)81 (30.8%)0.556Not tested10 (45.5%)4 (18.2%)8 (36.4%)Negative304 (49.8%)118 (19.3%)188 (30.8%)Not tested238 (50.9%)103 (22.0%)127 (27.1%)Positive315 (49.8%)122 (19.3%)196 (31.0%)Not tested237 (50.7%)103 (22.1%)127 (27.2%)	Negative	298 (49.4%)	128 (21.2%)	177 (29.4%)	0.491		
Anti-Rubella IgMPositive2 (40.0%)1 (20.0%)2 (40.0%)Negative382 (49.0%)160 (20.5%)237 (30.4%)Not tested168 (53.2%)6 4 (20.3%)8 (4 (6.6%)Anti-Rubella IgGPositive59 (50.0%)20 (16.9%)39 (33.1%)Negative326 (48.9%)141 (21.1%)200 (30.0%)Not tested167 (53.0%)64 (20.3%)84 (26.7%)Anti-CMV IgM10 (45.5%)4 (18.2%)8 (36.4%)Negative304 (49.8%)118 (19.3%)188 (30.8%)Not tested304 (49.8%)103 (22.0%)127 (27.1%)Positive15 (49.8%)122 (19.3%)196 (31.0%)Not tested315 (49.8%)130 (22.1%)127 (27.0% 1%)	Not tested	171 (52.8%)	66 (20.4%)	87 (26.9%)			
Positive 2 (40.0%) 1 (20.0%) 2 (40.0%) Negative 382 (49.0%) 160 (20.5%) 237 (30.4%) Not tested 168 (53.2%) 64 (20.3%) 84 (26.6%) Anti-Rubella IgG 59 (50.0%) 20 (16.9%) 39 (33.1%) Negative 59 (50.0%) 20 (16.9%) 39 (33.1%) Negative 326 (48.9%) 141 (21.1%) 200 (30.0%) Not tested 167 (53.0%) 64 (20.3%) 84 (26.7%) Anti-CMV IgM 10 (45.5%) 4 (18.2%) 84 (36.4%) Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) Not tested 304 (49.8%) 103 (22.0%) 127 (27.1%) Anti-CMV IgG 135 (49.8%) 122 (19.3%) 196 (31.0%) Not tested 315 (49.8%) 122 (19.3%) 196 (31.0%) Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%)	Anti-Rubella IgM						
Negative $382 (49.0\%)$ $160 (20.5\%)$ $237 (30.4\%)$ ***Not tested $168 (53.2\%)$ $64 (20.3\%)$ $84 (26.6\%)$ ***Anti-Rubella IgGPositive $59 (50.0\%)$ $20 (16.9\%)$ $39 (33.1\%)$ 0.556 Negative $326 (48.9\%)$ $141 (21.1\%)$ $200 (30.0\%)$ 0.556 Not tested $167 (53.0\%)$ $64 (20.3\%)$ $84 (26.7\%)$ 0.556 Anti-CMV IgM $10 (45.5\%)$ $4 (18.2\%)$ $8 (36.4\%)$ 0.604 Negative $304 (49.8\%)$ $118 (19.3\%)$ $188 (30.8\%)$ 0.604 Not tested $238 (50.9\%)$ $103 (22.0\%)$ $127 (27.1\%)$ 0.604 Anti-CMV IgG $122 (19.3\%)$ $196 (31.0\%)$ 0.306 Positive $315 (49.8\%)$ $122 (19.3\%)$ $196 (31.0\%)$ 0.306 Not tested $237 (50.7\%)$ $103 (22.1\%)$ $127 (27.2\%)$ 0.306	Positive	2 (40.0%)	1 (20.0%)	2 (40.0%)			
Not tested 168 (53.2%) 64 (20.3%) 84 (26.6%) Anti-Rubella IgG Positive 59 (50.0%) 20 (16.9%) 39 (33.1%) Negative 326 (48.9%) 141 (21.1%) 200 (30.0%) Not tested 167 (53.0%) 64 (20.3%) 84 (26.7%) Anti-CMV IgM 10 (45.5%) 4 (18.2%) 8 (36.4%) Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) Not tested 238 (50.9%) 103 (22.0%) 127 (27.1%) Anti-CMV IgG V Sister Sister Positive 315 (49.8%) 122 (19.3%) 196 (31.0%) 0.306 Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%) 0.306	Negative	382 (49.0%)	160 (20.5%)	237 (30.4%)	****		
Anti-Rubella IgG Positive 59 (50.0%) 20 (16.9%) 39 (33.1%) Negative 326 (48.9%) 141 (21.1%) 200 (30.0%) Not tested 167 (53.0%) 64 (20.3%) 84 (26.7%) Anti-CMV IgM 10 (45.5%) 4 (18.2%) 8 (36.4%) Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) Negative 304 (49.8%) 103 (22.0%) 127 (27.1%) Anti-CMV IgG 59 (50.7%) 122 (19.3%) 196 (31.0%) Positive 315 (49.8%) 122 (19.3%) 127 (27.2%) Positive 315 (49.8%) 122 (19.3%) 196 (31.0%) Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%)	Not tested	168 (53.2%)	64 (20.3%)	84 (26.6%)			
Positive 59 (50.0%) 20 (16.9%) 39 (33.1%) Negative 326 (48.9%) 141 (21.1%) 200 (30.0%) 0.556 Not tested 167 (53.0%) 64 (20.3%) 84 (26.7%) 0.556 Anti-CMV IgM Positive 10 (45.5%) 4 (18.2%) 8 (36.4%) 0.604 Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) 0.604 Not tested 238 (50.9%) 103 (22.0%) 127 (27.1%) 0.604 Anti-CMV IgG 315 (49.8%) 122 (19.3%) 196 (31.0%) 0.306 Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%) 0.306	Anti-Rubella IgG						
Negative 326 (48.9%) 141 (21.1%) 200 (30.0%) 0.556 Not tested 167 (53.0%) 64 (20.3%) 84 (26.7%) Anti-CMV IgM Positive 10 (45.5%) 4 (18.2%) 8 (36.4%) Ange (49.8%) 118 (19.3%) 188 (30.8%) 0.604 Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) 0.604 Not tested 238 (50.9%) 103 (22.0%) 127 (27.1%) 0.604 Anti-CMV IgG	Positive	59 (50.0%)	20 (16.9%)	39 (33.1%)			
Not tested 167 (53.0%) 64 (20.3%) 84 (26.7%) Anti-CMV IgM Positive 10 (45.5%) 4 (18.2%) 8 (36.4%) Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) Not tested 238 (50.9%) 103 (22.0%) 127 (27.1%) Anti-CMV IgG Year Second Seco	Negative	326 (48.9%)	141 (21.1%)	200 (30.0%)	0.556		
Anti-CMV IgM Positive 10 (45.5%) 4 (18.2%) 8 (36.4%) Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) Not tested 238 (50.9%) 103 (22.0%) 127 (27.1%) Anti-CMV IgG Positive 315 (49.8%) 122 (19.3%) 196 (31.0%) 0.306 Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%) 1306	Not tested	167 (53.0%)	64 (20.3%)	84 (26.7%)			
Positive 10 (45.5%) 4 (18.2%) 8 (36.4%) Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) Not tested 238 (50.9%) 103 (22.0%) 127 (27.1%) Anti-CMV IgG State State State Positive 315 (49.8%) 122 (19.3%) 196 (31.0%) Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%)	Anti-CMV lgM						
Negative 304 (49.8%) 118 (19.3%) 188 (30.8%) 0.604 Not tested 238 (50.9%) 103 (22.0%) 127 (27.1%)	Positive	10 (45.5%)	4 (18.2%)	8 (36.4%)			
Not tested 238 (50.9%) 103 (22.0%) 127 (27.1%) Anti-CMV IgG Positive 315 (49.8%) 122 (19.3%) 196 (31.0%) 0.306 Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%) 0.306	Negative	304 (49.8%)	118 (19.3%)	188 (30.8%)	0.604		
Anti-CMV IgG Second State<	Not tested	238 (50.9%)	103 (22.0%)	127 (27.1%)			
Positive 315 (49.8%) 122 (19.3%) 196 (31.0%) 0.306 Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%) 0.306	Anti-CMV IgG						
Not tested 237 (50.7%) 103 (22.1%) 127 (27.2%) 0.500 Total 552 (50.2%) 225 (20.5%) 222 (20.4%) 223 (20.4%)	Positive	315 (49.8%)	122 (19.3%)	196 (31.0%)	0.306		
	Not tested	237 (50.7%)	103 (22.1%)	127 (27.2%)	0.000		
IULAL DD2 (DU.2%) Z2D (ZU.5%) SZS (Z9.4%)	Total	552 (50.2%)	225 (20.5%)	323 (29.4%)			

***The validity conditions for the chi-square test were not met; in some cells the expected value is less than 5, Ig: Immunoglobulin, HCV: Hepatitis C virus, HBsAg: Hepatitis B surface antigen, CMV: Cytomegalovirus in Turkey. Additionally, the seroprevalence data cover only a limited time period (2018-2020), which limits the ability to assess long-term trends. Second, the low positivity rates of some serological tests reduced the statistical power of chisquare analysis because of low cell frequencies. This limitation especially affected the analysis of rare infections (e.g., anti-HCV positivity), making it challenging to derive statistically significant results. Furthermore, due to limited access to healthcare services among the refugee population, some individuals may not have been able to receive regular healthcare, limiting the representativeness of serological test results. Future studies should consider the effects of these variables on infection prevalence by incorporating them into the analysis.

Conclusion

Infectious diseases are prevalent among pregnant women in Turkey. This situation is associated with challenges to healthcare access and inadequate hygiene conditions in the migrant population. Expanding screening and vaccination programs is essential to reduce the spread of these infections and to protect the health of refugee women. In addition, improving living conditions and ensuring regular health screenings for refugees play critical roles in preventing infectious diseases.

Ethics

Ethics Committee Approval: The study was approved by University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital Ethics Committee on March 06, 2024, with approval number 2024/02-07.

Informed Consent: Retrospective study.

Footnotes

Authorship Contributions

Surgical and Medical Practices: İ.A., Concept: İ.A., Z.S.V., Design: İ.A., Data Collection or Processing: İ.A., Z.S.V., Analysis or Interpretation: İ.A., Z.S.V., Literature Search: İ.A., Z.S.V., Writing: İ.A., Z.S.V.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

 Delva W, Keet IPM, van den Akker M, et al. Migrants' vulnerability to infectious diseases: Comparative analysis in refugee populations. Epidemiol Infect. 2021;149.

- Kariuki SM, Kinyua M, Mugo R, et al. Seroprevalence and seroconversion of TORCH infections among pregnant women in Kenya. Epidemiol Infect. 2019;147:e261.
- 3. World Health Organization. Global Hepatitis Report, 2017. Geneva: WHO Press; 2017. Accessed on: October 30, 2024. Available from: https://www. who.int/hepatitis/publications/global-hepatitis-report2017/en/
- Fakoya I, Alvarez-Del Arco D, Monge S, et al. HIV among migrants from high-prevalence countries in the EU/EEA: A systematic review of prevalence and risk factors. BMC Public Health. 2015;15:1032.
- Lee B, Yu S, Ke H, et al. Health challenges for Syrian and Afghan refugees: Infectious diseases in displacement settings. Lancet Infect Dis. 2023;23:405-12.
- 6. El-Khatib Z, Scoglio B. Toxoplasmosis and rubella seroprevalence among pregnant refugee women. J Infect Dev Ctries. 2020;14:1052-9.
- 7. Mugo R, Kinyua M, Kariuki S, et al. High CMV prevalence among migrant women: A public health challenge. BMC Infect Dis. 2019;19:321.
- 8. Moloney G, Perera S, Roberts K. Infectious diseases in migrant populations: A global perspective on risk factors. Lancet Glob Health. 2022;10.
- 9. Monge S, Del Amo J. Hepatitis B virus infection in EU migrant populations: A review. BMC Infect Dis. 2020;20:15.
- Rodger AJ, Cambiano V, Bruun T, et al. Mortality in HIV-positive migrant populations in Europe: Collaborative cohort analysis. AIDS. 2021;35:1611-20.
- 11. Sarfraz M, Tamer H. Maternal health challenges in refugee women: Risks of infectious diseases during pregnancy. Int J Environ Res Public Health. 2023;20:2170.
- 12. Vauloup-Fellous C, Picone O, Cordier A, et al. Rubella, CMV, and toxoplasmosis screening in pregnancy: An update. Clin Microbiol Infect. 2019;25:158-64.
- De Schutter S, Devleesschauwer B, Ducres S. Preventive healthcare for migrant populations: Addressing infectious disease risks. Public Health Rev. 2023;44:220.
- 14. Saseetharran A, Hiebert L, Gupta N, et al. Prevention, testing, and treatment interventions for hepatitis B and C in refugee populations: results of a scoping review. BMC Infect Dis. 2023;23:866.
- Gürses G, Doni NY, Şimşek Z, et al. Evaluation of T. gondii, rubella, and cytomegalovirus seroprevalences among female Syrian refugees in Sanliurfa, Turkiye. J Infect Dev Ctries. 2024;18:964-71.
- Fahme SA, Fakih I, Ghassani A, et al. Sexually transmitted infections among pregnant Syrian refugee women seeking antenatal care in Lebanon. J Travel Med. 2024;31:taae058.
- Hansu K, Cikim IG. Comparison of hepatitis B surface antigen, antihepatitis B surface, and anti-hepatitis C virus prevalence in Syrian refugee pregnant women and Turkish pregnant women. Rev Assoc Med Bras. 2023;69.
- Köse Ş, Ödemiş İ, Çelik D, et al. Hepatitis A, B, C and HIV seroprevalence among Syrian refugee children admitted to outpatient clinics. Le Infezioni in Medicina. 2017;25:339-43.
- Bakacak M, Serin S, Aral M, et al. Seroprevalance Differences of Toxoplasma Between Syrian Refugees Pregnants and Indigenous Turkish Pregnants in Kahramanmaraş. Turkiye Parazitol Derg. 2015;39:94-7.
- Hansu K, Özdemir H, Hansu İ, et al. Comparison of the Toxoplasma seroprevalence rates in Syrian refugee pregnant women and turkish pregnant women. Turkiye Parazitol Derg. 2021;45:247-51.